An Assessment of the Safety and Pharmacokinetics of Ascending Doses of SANGUINATE™ in Healthy Volunteers.
Phase of Trial: Phase I
Latest Information Update: 09 Jan 2015
At a glance
- Drugs PEG-haemoglobin carbon monoxide (Primary)
- Indications Hypoxia
- Focus Adverse reactions
- Sponsors Prolong Pharmaceuticals
- 09 Jan 2015 Last checked against ClinicalTrials.gov record.
- 26 Oct 2013 New trial record
- 03 Oct 2013 Results have been presented at the Joint Conference of the International Federation of Artificial Organs and the Japan Society of Artificial Organs according to a Prolong Pharmaceuticals media release. Results were also reported in the media release.